NORFOLK PLANT SCIENCES LIMITED

Financial Health Score: C+ (Stable but requiring ongoing care)

Explanation: Norfolk Plant Sciences Limited has been successfully resuscitated from a state of technical insolvency in 2024 back to a positive net asset position in 2025. This remarkable recovery is due entirely to a significant "capital transfusion" from investors via a debt-to-equity conversion and share issuance. However, the underlying business metabolism—its ability to generate revenue—remains impaired, as evidenced by deeply negative retained earnings and ongoing operational losses. The patient is out of the emergency room, but still requires life support in the form of investor capital.

Key Vital Signs

• Net Assets (Constitution): £227,900 (Positive)
  • Interpretation: A massive improvement from the 2024 figure of negative £305,355. The patient’s structural foundation has been repaired, moving the company out of the "danger zone" of negative equity.
• Cash Reserves (Blood Pressure): £278,278
  • Interpretation: Healthy pulse. Cash has increased nearly threefold from £103,413 in 2024. This indicates fresh capital has entered the bloodstream, providing the necessary oxygen (funding) to continue operations.
• Current Liabilities (Cholesterol/Blockages): £51,704
  • Interpretation: Dramatically reduced from £409,594. The major blockage—an £381,000 convertible loan note—has been successfully cleared through conversion into equity, significantly improving short-term financial flexibility.
• Retained Earnings / P&L Reserve (Medical History): (£1,216,589)
  • Interpretation: Chronic condition. The accumulated losses have grown significantly from (£741,063), indicating that the business continues to burn through cash faster than it generates it. This highlights a pre-revenue or R&D-heavy business model.
• Share Capital & Premium (Transfusion): £8,815 (Capital) / £1,435,674 (Premium)
  • Interpretation: Share capital increased from £5,423, and the share premium account surged from £430,285. This is the primary medication that cured the 2024 insolvency, showing strong backing from shareholders who converted debt and injected new capital at a significant premium.

Diagnosis

The Patient: Norfolk Plant Sciences Limited is an R&D biotechnology firm (focusing on GM purple tomatoes) that operates in a high-burn, pre-commercialization environment.

The Condition: In the 2024 financial year, the company exhibited severe symptoms of financial distress. With liabilities vastly exceeding assets, the company was technically insolvent—a patient in critical condition relying on life support from its lenders.

The Treatment: Over the 2025 financial year, the directors performed a successful financial surgery. They converted a toxic £381,000 unsecured convertible loan note into equity, simultaneously clearing the debt and restructuring the balance sheet. Furthermore, the substantial increase in the share premium account indicates that additional equity funding was raised from investors.

Current State: While the balance sheet looks much healthier on the surface, the underlying disease—operational cash burn—remains. The P&L reserve deteriorated by approximately £475,000 over the year, meaning the company's "metabolism" is still consuming far more energy than it produces naturally. The company is entirely reliant on continuous "transfusions" of investor capital to survive until its biotechnology can be commercialized.

Recommendations

1. Monitor the Cash Runway Vigilantly: With £278k in cash and an apparent annual burn rate approaching £475k (based on P&L deterioration), the current cash reserves may provide a runway of less than a year. Management must closely monitor cash flow and begin planning the next round of fundraising well before the patient flatlines.
2. Target Milestone-Based Revenue (Improve Metabolism): To reduce reliance on equity transfusions, the business should explore licensing its intellectual property, securing research grants, or forming strategic partnerships that can provide milestone payments to offset the R&D burn rate.
3. Maintain Strong Investor Relations: Because the company's survival currently depends on the continued willingness of investors to convert debt and inject share premium, transparent and frequent communication with shareholders is the most critical aspect of ongoing care.
4. Control Operational Overhead: Review all non-essential R&D and administrative expenditures to stretch the current cash runway as far as possible while commercial applications are finalized.